TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Computed Tomography for Lung Cancer Screening

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Scheduled for LDCT screening~2. Current smoking (every day/some days)~3. At least weekly use of the Internet~4. Current ownership of cell phone with a text messaging plan~5. Willing to receive study text messages.~6. Ability to complete all aspects of the study~7. Ability to provide signed informed consent~Exclusion Criteria:~1. Current (in the past 30 days) use of tobacco cessation medication or participation in tobacco cessation treatment.~2. Those with a condition deemed by the investigators to be exclusionary to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- UC (Type: ACTIVE_COMPARATOR): Usual Care
- WEB+TXT (Type: ACTIVE_COMPARATOR): Digital Intervention
- WEB+TXT+TTS (Type: ACTIVE_COMPARATOR): Digital plus Counseling Intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Trial of Home-Based Palliative Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Patient Inclusion Criteria:~* Serious illness with 12-24 month life expectancy~* Homebound~* Need for skilled nursing care (only at KP Southern California)~* English or Spanish speakers~Patient Exclusion Criteria:~- Currently receiving HBPC~Caregiver Inclusion Criteria:~* Non-professional family, friend or other caregiver~* English or Spanish speakers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard HBPC (Type: ACTIVE_COMPARATOR): Patients and caregivers in standard HBPC will continue to receive usual care from the palliative care team which includes home visits
- Tech-supported HBPC (Type: EXPERIMENTAL): Patients and caregivers in tech-supported HBPC will receive synchronous video visits with a provider (physician or nurse practitioner) while the nurse is in the patient's home. Home visits by the palliative care team will be determined based on patients/caregivers' needs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Multi-modality Imaging of Ischemia With 18F-FDG PET and CTA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with suspected CAD referred for CTA and found to have moderate CAD stenoses and 20 normal volunteers with less than 5% probability of CAD.~2. Age ≥ 18 years~Exclusion Criteria:~1. Inability to undergo stress protocol due to co-morbidities~2. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 18F-FDG PET imaging (Type: EXPERIMENTAL): Positron Emission Tomography nuclear stress scan following either pharmacologic or treadmill stress test with radiopharmaceutical injection at peak stress or within 1 hour following peak stress.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant female \> 18 years of age;~* Documentation of heart failure and who are in NYHA class II or III;~* Documented history of symptomatic AF \< 6 months in duration at the time of presentation, currently in AF at the time of the external electrical cardioversion, and successfully restored to normal sinus rhythm;~* Percutaneous coronary intervention (PCI) patients who can be placed on anticoagulation with warfarin post-cardioversion (and not on rivaroxaban or dabigatran);~* Demonstration of preserved ejection fraction (EF) by echocardiography;~* Echocardiographic evidence of impaired diastolic filling.~Exclusion Criteria:~* Known history of permanent or long-standing AF (\> 6 months);~* Other acutely reversible causes of AF, including but not limited to: hyperthyroidism, pericarditis, myocarditis or pulmonary embolism;~* Known history of cirrhosis;~* NYHA Class IV;~* Myocardial Infarction, unstable angina, or coronary artery bypass graft surgery within three months prior to screening;~* Percutaneous coronary intervention (PCI) within 4 weeks prior to screening, if these patients need to be placed on rivaroxaban or dabigatran post-cardioversion;~* Clinically significant valvular disease;~* Clinically significant pulmonary disease;~* Stroke within 3 months prior to screening;~* Creatinine clearance \< 30 mL/min as calculated by Cockcroft-Gault formula;~* Use of anti-arrhythmic drugs (Class Ia or IIIc) within 3 months prior to screening;~* Concurrent use of drugs considered strong inhibitors of CYP3A;~* Concurrent use of drugs considered as CYP3A inducers;~* Prior treatment with ranolazine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranolazine (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Liberal Versus Restrictive Transfusion During Symptomatic Moderate Anemia After Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 and able to give consent~* Hip arthroplasty or hip revision arthroplasty~* Haemoglobin \> 4.8 mmol/L and \< 6.0 mmol/L on the first postoperative day~* Dizziness score ≥ 2.~Exclusion Criteria:~* Large ongoing bleeding~* Has already received RBC during the current admission~* New onset of cardiac arrhythmia suspected to be related to anemia~* Severe ischemic heart disease~* Renal failure with dialyses or oligouria / anuria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RBC transfusion (Type: ACTIVE_COMPARATOR): Administration of up to 2 RBC units on the first postoperative day.~(1 unit at a time followed by evaluation of the primary outcome measure)
- Restrictive: Colloid infusion (Type: PLACEBO_COMPARATOR): Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Perceptions of Their Own Body and of the Body of Their Child Among Young Mothers With Anorexia Nervosa

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* adult woman, understanding and reading French, delivering in the CHU (Centre Hospitalier Universitaire) Clermont-Ferrand maternity hospital between 01/15/2020 and 01/14/2021, and with active or in remission anorexia nervosa diagnosed according to DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders)~* able to accept participating to the study~* Affiliated to the national healthcare system~Exclusion Criteria:~* delivery before 32 weeks of amenorrhea (significant prematurity and extreme prematurity)~* death in utero or medically-motivated induced termination~* infant death during labour or post-partum~* refusal to participate

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient group (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Eosinophilic Chronic Rhinosinusitis Utilizing Betamethasone Dipropionate Nasal Cream

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with a clinically confirmed diagnosis of eCRS by a ENT undergoing maximal medical therapy as part of their standard of care.~* Having undergone functional endoscopic sinus surgery at least 6 months prior to enrolment.~* Participants with an endoscopic bilateral nasal polyp score of ≤5 out of a maximum score of 8~* Score \> 2 on disease severity visual analogue scale (VAS)~* A minimum body weight \>=40 kilograms (kg) at screening visit~* Gender: Male or female (females of childbearing potential must use adequate birth control methods and not plan to get pregnant during the course of the study).~* Informed consent: Willingness to give written informed consent and willingness to participate to and comply with the study.~* Age ≥18 but \<80 years.~Exclusion Criteria:~* Subjects with known hypersensitivity or contraindications to Betamethasone Dipropionate, corticosteroids or topical anaesthesia.~* Subjects with sino-nasal abnormalities, disease or implanted devices that prevent application of the therapy.~* Previous enrolment in this study.~* Subjects currently required systemic corticosteroid use or receiving biologic therapy as part of their disease management plan or who meet the PBS criteria for severe lower airway disease.~* Subjects with history or current glaucoma or cataract or if they have abnormal IOP at screening or pre-treatment (abnormal IOP is defined as greater than 21 mm Hg).~* Subjects with other conditions that could lead to elevated eosinophils such as Hypereosinophilic Syndromes, including Churg-Strauss Syndrome, or Eosinophilic Esophagitis.~* Subjects with acute sinusitis.~* Subjects with known immunodeficiency.~* Subjects with Diabetes (Type 1).~* Subjects with cystic fibrosis.~* Pregnant subjects or subjects currently lactating as the effect on human pregnancy is unknown.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Betamethasone Dipropionate Nasal Cream 0.0644% Treatment (Type: EXPERIMENTAL): Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Diverting Loop Ileostomy: With or Without Rod

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients scheduled for planned protective loop ileostomy~Exclusion Criteria~* patients with long-term use of corticosteroids (\> 15 mg prednisolone equivalent)~* immunosuppressive agent rapamune

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: OTHER): diverting loop ileostomy with rod
- B (Type: OTHER): diverting loop ileostomy without rod

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Surgical Outcomes Following Neurectomy Based Upon Response to Local Anesthetic Injection in Chronic Groin Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (18 years of older)~* Chronic groin pain~Exclusion Criteria:~* Not a surgical candidate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ilioinguinal Nerve Block (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Demonstrate willingness to participate in the study and comply with its procedures by signing a written informed consent.~* Equal to or greater than 18 years.~* Confirmed chronic hepatitis C with hepatitis C virus (HCV) RNA positive in plasma.~* No previous use of PegIntron Pen.~Exclusion Criteria:~* Hypersensitivity to the active substance or to any interferon or to any of the excipients.~* Pregnant women.~* Women who are breastfeeding.~* Existence of or a history of severe psychiatric condition, particularly severe depression, suicidal ideation or suicide attempt.~* A history of severe pre-existing cardiac disease, including unstable or uncontrolled cardiac disease in the previous six months.~* Severe debilitating medical condition, including patients with chronic renal failure or creatinine clearance \< 50 ml/minute.~* Auto immune hepatitis or a history of autoimmune disease.~* Severe hepatic dysfunction or decompensated cirrhosis of the liver.~* Pre-existing thyroid disease unless it can be controlled with conventional treatment.~* Epilepsy and/or compromised central nervous system (CNS) function.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Genotype 1 CHC Participants (Type: None): None
- Non-genotype 1 CHC participants (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Individualized Transcranial Direct Current Stimulation for Gait Function in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Healthy adult men and women without history of central nervous system disease and abnormalities~Exclusion Criteria:~* Under 18 years old, 75 years old or older~* A person who has inserted a metal object in a skull~* A person with complete occlusion of the carotid artery~* A person with epilepsy~* Pregnant and lactating women~* Who is not eligible for the test

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Individualized stimulation group (Type: EXPERIMENTAL): Based on transcranial direct current stimulation (tDCS) simulation, individualized stimulation on leg motor areas during 30 minutes.
- Conventional stimulation group (Type: ACTIVE_COMPARATOR): Conventional stimulation on leg motor areas during 30 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Digital Therapeutic for Adolescent Depressive Symptoms in Hematology, Oncology, and Weight Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 13 and 22~* Moderate- severe self-reported symptoms of depression at baseline (PHQ-8 \>= 5)~* Have a comorbid medical condition and under the care of a healthcare provider at CHST~* English fluency and literacy of adolescent; English or Spanish fluency and literacy of consenting legal guardian if under 18~* Access to a compatible smartphone (or other device) and operating system (i.e., capable of installing the app from the Google Play or Apple App Store; list will be provided to participants) and regular internet access~* Willing to provide informed consent/assent and have legal guardian willing to provide informed consent (if required)~Exclusion Criteria:~* Concurrent psychotherapy: Have met with a psychologist for intervention (not assessment) for 30 minutes or more, more than once in the 3 weeks prior to enrollment as determined by the study team~* Change in psychotropic medication (initiation or change in dose) within the past 30 days prior to enrollment~* Suicide attempt within the past year as determined at eligibility screening~* Active suicidal ideation with intent as determined at eligibility screening~* Previously participated in user testing or clinical testing of the Spark app~* Participating in any other psychiatric or psychological treatment based clinical research at the time of enrollment and up to two months prior to enrollment or planning to participate in any other psychiatric or psychological treatment based clinical research during the study intervention period (5 weeks)~* Any condition, comorbidity, or event that, in the opinion of the investigator, will prevent the participant from adhering to the protocol or benefiting from the treatment (e.g., unable to provide informed assent or consent) or will prevent investigators from being able to ensure safety (e.g., will be leaving the country during study time period)

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- SparkRx (Type: EXPERIMENTAL): 5-week CBT-based mobile intervention for adolescents with depressive symptoms
- Educational Control (Type: ACTIVE_COMPARATOR): 5-week mobile control with education about depression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevalence of POU4F3 and SLC17A8 Mutations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Patients with a~  1. suggestive neurosensory Deafness: The characteristics of the deafness will be determined from the data of the questionnaire, of the interrogation, the examination and results of the tonal audiometry.~     \*Neurosensory deafness: Audiometrics measurement(difference between the tonal audiometric average loss for the frequencies 0,5, 1, 2 and 4 kHz in air conduction and in osseous conduction) \< 15 dB for each of both ears.~    * Bilateral symetric: difference between the audiometric thresholds of both ears \< or = 15 dB for at least two frequencies.~    * Light to severe: The degree of deafness is defined according to the following classification (moderate hearing loss calculated on the frequencies 500 Hz, 1, 2 and 4 kHz): light hearing deficiency from 20 to 40 dB, moderate hearing deficiency of 40 to 70 dB, severe hearing deficiency of 70 in 90 dB and deep hearing deficiency beyond 90 dB.~    * Whose thresholds frequency by frequency in tonal audiometry (air conduction) are superior to the thresholds of the 90th percentile of the standard ISO 7029.~    * Without environmental exposition factors.~ 2. Dominant autosomal transmission diagnosed from one of the following elements:~     * Deafness at a father and his son~    * Deafness at a father and his daughter outside a suggestive context of a dominant form X-related. (deep deafness at the father and light to moderate deafness in daughter)~    * Deafness at a mother and her daughter~    * Deafness at a mother and her son outside a suggestive context of a dominant X-related(light to moderate deafness at the mother, and deep deafness at the son)~    * Deafness at a patient whose a dead parent had a sure or likely deafness according to the criteria of diagnosis mentioned previously~ 3. given the consent to participate at this clinical study~Exclusion Criteria:~* Suggestive symptom of a polymalformative syndrom~* familial Consanguinity~* Age \< 18 years~* Deafness of transmission or mixed~* Deafness of asymmetric or fluctuating perception~* Prelingual deep Deafness~* Pathology of the ear (otospongiose, disease of Ménière, neurinome of the acoustics)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deafness patients (Type: None): Deafness patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* Registration to CALGB 9480 or 9583~* Samples collected and shipped appropriately~* Institutional Review Board (IRB) review and approval at the institution where the laboratory work will be performed is required

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): Previously collected plasma and urine samples are analyzed for VEGF via ELISA, plasma samples are analyzed for CgA and IL-6 via ELISA, hK2 via immunometric assay, plasma samples are analyzed for PSA via Tandem-R PSA kit, plasma samples are analyzed for TNF-alpha, sTNF-R1, and IL-8 via quantikine IL-8 immunoassay.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility